Gómez-Ramiro, MartaVieta i Pascual, Eduard, 1963-Fico, GiovannaIsayeva, UlkerDe Prisco, MicheleOliva, VincenzoSolé Cabezuelo, BrisaMontejo Egido, LauraGrande i Fullana, IriaArbelo, NéstorPintor Pérez, LuisCarpiniello, BernardoManchia, MirkoMurru, Andrea2EPs Group2024-04-242024-04-242022-10-200924-977Xhttps://hdl.handle.net/2445/210403Several psychotropic drugs, including antidepressants (AD), mood stabilizers, and antipsychotics (AP) have been suggested to have favorable effects in the treatment of COVID-19. The aim of this systematic review and meta-analysis was to collect evidence from studies concerning the scientific evidence for the repurposing of psychotropic drugs in COVID-19 treatment. Two independent authors searched PubMed-MEDLINE, Scopus, PsycINFO, and ClinicalTrials.gov databases, and reviewed the reference lists of articles for eligible articles published up to 13th December, 2021. All computational, preclinical and clinical (observational and/or RCTs) studies on the effect of any psychotropic drug on Sars-CoV-2 or patients with COVID-19 were considered for inclusion. We conducted random effect meta-analyses on clinical studies reporting the effect of AD or AP on COVID-19 outcomes. 29 studies were included in the synthesis: 15 clinical, 9 preclinical, and 5 computational studies. 9 clinical studies could be included in the quantitative analyses. AD did not increase the risk of severe COVID-19 (RR= 1.71; CI 0.65-4.51) or mortality (RR=0.94; CI 0.81-1.09). Fluvoxamine was associated with a reduced risk of mortality for COVID-19 (OR=0.15; CI 0.02-0.95). AP increased the risk of severe COVID-19 (RR=3.66; CI 2.76-4.85) and mortality (OR=1.53; CI 1.15-2.03). Fluvoxamine might be a possible candidate for psychotropic drug repurposing in COVID-19 due to its anti-inflammatory and antiviral potential, while evidence on other AD is still controversial. Although AP are associated with worse COVID-19 outcomes, their use should be evaluated case to case and ongoing treatment with antipsychotics should be not discontinued in psychiatric patients.73 p.application/pdfengcc-by-nc-nd (c) Elsevier B.V., 2022http://creativecommons.org/licenses/by-nc-nd/4.0/PsicofàrmacsMetaanàlisiRessenyes sistemàtiques (Investigació mèdica)COVID-19AntidepressiusAntipsicòticsPsychotropic drugsMeta-analysisSystematic reviews (Medical research)COVID-19AntidepressantsAntipsychotic drugsinfo:eu-repo/semantics/article7353652024-04-24info:eu-repo/semantics/openAccess36495858